Clinical Trial of Jinzhen Oral Liquid in Treating Children With COVID-19 Infection
COVID-19, Child, Only
About this trial
This is an interventional treatment trial for COVID-19
Eligibility Criteria
Inclusion Criteria:
1. Meet the diagnostic criteria of novel coronavirus infected patients in COVID-19 Diagnosis and Treatment Protocol (Trial Version 9);
2. Asymptomatic infection or clinical classification of mild or common type;
3. Aged from 3 to 18 years;
4. The informed consent process was in accordance with the regulations, and the legal guardian or the children (≥8 years old) signed the informed consent form.
Exclusion Criteria:
1. Meet the severe/critical early warning indicators;
2. Children who used proprietary Chinese medicine of the same type for more than 3 days before enrollment;
3. Children with diarrhea.
Sites / Locations
- Phase I Clinical Research CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
treatment group
control group
Jinzhen oral liquid(for 3 years old, 10 ml once, twice a day; for 4 to 7 years old, 10 ml a time, 3 times a day; for 8 to 18 years old, 15 ml a time, 3 times a day)
The usage and dosage of Jinhua Qinggan granules were determined by the researcher according to the patient's condition and recorded truthfully